Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Kura Oncology, Inc. (KURA)

Pharmaceutical Preparations

https://www.kuraoncology.com

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/25/2015

Market Cap

1,484,027,092

Shares Outstanding

74,270,000

Weighted SO

74,272,111

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

PTGX --.--%

MRUS --.--%

REPL --.--%

CERE --.--%

KALV --.--%

CRNX --.--%

THRX --.--%

VRDN --.--%

GRCL --.--%

Beta

0.8770

Last Div

0.0000

Range

7.41-24.17

Chg

-0.0850

Avg Vol

738543

Mkt Cap

1484027092

Exch

NASDAQ

Country

US

Phone

858 500 8800

DCF Diff

19.1053

DCF

0.2747

Div Yield

0.0000

P/S

1168.5253

EV Multiple

-7.4664

P/FV

3.5996

Div Yield %

0.0000

P/E

-9.2307

PEG

3.7477

Payout

0.0000

Current Ratio

14.9403

Quick Ratio

14.9403

Cash Ratio

1.3507

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

869.9307

CCC

-869.9307

Gross Margin

0.3181

Op Margin

-154.5039

Pretax Margin

-143.1102

Net Margin

-143.1102

Eff Tax Rate

-0.0191

ROA

-0.3528

ROE

-0.4043

ROCE

-0.4074

NI/EBT

1.0000

EBT/EBIT

0.9263

EBIT/Rev

-154.5039

Debt Ratio

0.0211

D/E

0.0234

LT Debt/Cap

0.0181

Total Debt/Cap

0.0228

Int Coverage

-248.3797

CF/Debt

-14.2065

Equity Multi

1.1052

Rec Turnover

0.0000

Pay Turnover

0.4196

Inv Turnover

0.0000

FA Turnover

0.1603

Asset Turnover

0.0025

OCF/Share

-1.7858

FCF/Share

-1.7873

Cash/Share

5.6734

OCF/Sales

-121.8181

FCF/OCF

1.0009

CF Coverage

-14.2065

ST Coverage

-66.8578

CapEx Coverage

-1137.5662

Div&CapEx Cov

-1137.5662

P/BV

3.5996

P/B

3.5996

P/S

1168.5253

P/E

-9.2307

P/FCF

-9.5840

P/OCF

-10.8441

P/CF

-10.8441

PEG

3.7477

P/S

1168.5253

EV Multiple

-7.4664

P/FV

3.5996

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 01, 23:00 Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML GlobeNewswire Inc. Sep 30, 22:30 Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology Benzinga Dec 22, 12:50 Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst Benzinga Dec 22, 12:50 Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst GlobeNewswire Inc. Dec 08, 07:30 Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial GlobeNewswire Inc. Nov 28, 07:30 Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit GlobeNewswire Inc. Nov 02, 07:30 Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC GlobeNewswire Inc. Oct 30, 07:30 Kura Oncology to Participate in Three Upcoming Investor Conferences

Revenue Product Segmentation